T1	Participants 96 159	elderly adults with newly diagnosed acute myelogenous leukemia.
T2	Participants 204 272	elderly adults with newly diagnosed acute myelogenous leukemia (AML)
T3	Participants 435 558	phase 2 trial in 84 adults (age range, 70-90 years; median, 76 years) who were not candidates for conventional chemotherapy
